In the BioHarmony Drug Report Database

"Preview" Icon

Besifloxacin

Besivance (besifloxacin) is a small molecule pharmaceutical. Besifloxacin was first approved as Besivance on 2009-05-28. It is used to treat bacterial conjunctivitis, bacterial infections, and protozoan infections in the USA. Besivance’s patents are valid until 2031-01-09 (FDA).

 

Trade Name

 

Besivance
 

Common Name

 

besifloxacin
 

ChEMBL ID

 

CHEMBL1201760
 

Indication

 

bacterial conjunctivitis, bacterial infections, protozoan infections
 

Drug Class

 

Antibacterials (quinolone derivatives)

Image (chem structure or protein)

Besifloxacin structure rendering